期刊文献+

MMP-2和TIMP-2对结核性和恶性胸腔积液鉴别诊断价值

THE VALUE OF MATRIX METALLOPROTEINASE 2 AND TISSUE INHIBITOR OF METALLOPROTEINASE 2 IN DIFFERENTIAL DIAGNOSIS BETWEEN TUBERCULOUS AND MALIGNANT PLEURAL EFFUSION
下载PDF
导出
摘要 目的探讨胸腔积液中基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶组织抑制因子-2(TIMP-2)水平对结核性胸腔积液及恶性胸腔积液的鉴别诊断价值。方法采用ELISA法,检测34例结核性胸腔积液、35例肺部肿瘤并胸腔积液病人胸腔积液中MMP-2和TIMP-2水平,并进行比较。结果恶性胸腔积液组MMP-2和TIMP-2水平均明显高于结核性胸腔积液组,差异有显著性(t=7.099、8.515,P<0.01)。两组MMP-2/TIMP-2比值差异无显著性(P>0.05)。诊断特异度与灵敏度TIMP-2均大于MMP-2。结论MMP-2和TIMP-2可以作为结核性胸腔积液和恶性胸腔积液的鉴别诊断标志。 Objective To assess the value of of matrix metalloproteinase 2 (MMP 2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in differentiating tuberculous from malignant pleural effusion. Methods Using ELISA, the levels of MMP- 2 and TIMP 2 in pleural effusion in 34 patients with tuberculous pleural effusion and 35 with malignant pleura1 effusion were detec ted and compared. Results The MMP-2 and TIMP-2 levels in malignant pleural fluid were markedly higher than that in tuberculous plenral fluid, with a significant difference between them (t=7. 099,8.515; P〈0.01), while the difference of MMP-2/TIMP- 2 ratio was not significant (P〉0.05). The sensitivity and specificity of TIMP 2 were higher than that of MMP-2. Conclusion MMP-2 and TIMP -2 can be used as differential diagnostic markers in tuberculous pleural effusion and malignant pleural effusion.
出处 《齐鲁医学杂志》 2009年第4期335-337,共3页 Medical Journal of Qilu
关键词 明胶酶A 基质金属蛋白酶组织抑制因子2 胸腔积液 结核 肺肿瘤 Gelatinase A Tissue inhibitor of metalloproteinase 2 Pleural effusions Tuberculosis Lung neoplasms
  • 相关文献

参考文献10

  • 1EICKELBERG O, SOMMERFELD C O, WYSER C, et al. MMP and TIMP expression pattern in pleural effusions of different origins[J]. Am J Respir Crit Care Med, 1997, 156 :1987-1992.
  • 2BAKER A H, EDWARDS D R, MURPHY G. Metalloprotei-nase inhibitors: biological actions and therapeutic opportunities [J]. CellSci, 2002,115:3719-3727.
  • 3RIVERA-MARRERO C A, SCHUYLER W, ROSER S, et al. Induction of MMP-9 mediated gelatinolytic activity in human monocytic ceils by cell wall components of Mycobacterium tuberculosis[J]. Microb Pathog, 2000,29: 231-244.
  • 4RIVERA-MARRERO C A, SCHUYLER W, ROSER S, et al. Tuberculosis induction of matrix metalloproteinase-9: the role of mannose and receptor-mediated mechanisms [J]. Physiol Lung Cell Mol Physiol, 2002,282:L546-L555.
  • 5KWANG JOO P, SUNG C H, SEUNG S S, et al. Expression of matrix metalloproteinase-2 in pleural effusions of tuberculosis and lung cancer[J]. Respiration, 2005,72: 166-175.
  • 6YAMAMURA T, NAKANISHI K, HIROI S, et al. Expression of membrane-type-1 matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas[J]. Lung Cancer, 2002,35 : 249-255.
  • 7IGLESIAS D, AIEGRE J, AIEMAN C, et al. Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions[J]. J Eur Respir, 2005,25 : 104-109.
  • 8SUZUKI M, LIZAZA T, FUJISAWA T, et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer[J]. Invasion & Metastasis, 1998,18 : 134-141.
  • 9JINGA D, BLIDARU A, CONDREA I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer., correlations with prognostic factors[J]. Cell Mol Med, 2006,10(2) :499-510.
  • 10李慧梅,肖伟,曹爱芳,王君,王岷,赵东.肺癌血清基质金属蛋白酶-2及其组织抑制因子的表达[J].肿瘤学杂志,2008,14(3):210-212. 被引量:2

二级参考文献7

  • 1王军,罗兵.基质金属蛋白酶及其抑制物与肿瘤相关性研究进展[J].实用医药杂志,2006,23(2):218-221. 被引量:12
  • 2Kopczynska E, Dancewicz M, Kowalewski J, et al. The serum concentration of metalloproteinase 9 and 2 in non- small cell lung cancer patients[J]. 2007, 22(132):539-541.
  • 3Sasaki H, Kiriyama M, Fukai I, et al. Elevated serum pro- MMP2 levels in patients with advanced lung cancer are not suitable as a prognostic marker[J]. Surg Today, 2002, 32(1):93-95.
  • 4Kolomecki K, Astepien H, Bartos M. Usefulness of VEGF, MMP-2, MMP-3, TIMP-2 serum level evaluation in patients with adrenal tumors[J]. Endocr Regul, 2001, 35(1): 9-16.
  • 5Jinga D, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors[J]. J Cell Mol Med, 2006, 10(2):499-510.
  • 6Gohji K, Fujimoto N, Ohkawa J, et al. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer[J]. Br J Cancer, 1998, 77(4):650-655.
  • 7陶雅军,陈英杰,任新,温冬青.组织金属蛋白酶抑制剂-2与大肠癌浸润转移的关系[J].实用肿瘤学杂志,2003,17(1):1-3. 被引量:5

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部